Phase 2 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 years or older
- People who are willing and able to sign a written consent form
- People who have been diagnosed with a type of large B-cell lymphoma (a blood cancer) confirmed by laboratory testing, as defined by recognised international classification systems
- People in most groups (Cohorts 1, 2, and 4) who have already received at least two previous treatments for their lymphoma, or people in one group (Cohort 3) who have received at least one previous treatment
- People whose lymphoma has come back after treatment or has not responded to treatment
- People who have at least one measurable area of disease that can be tracked on scans (confirm with trial site for exact measurement requirements)
- People who are reasonably physically functional — rated 0 or 1 on a standard medical activity scale for most groups, or 0 to 2 for one group (Cohort 5) (confirm with trial site)
- People whose blood test results show adequate levels of certain immune and blood cells (neutrophils, platelets, and lymphocytes) above specific thresholds
Who may not be able to join:
- People who have had another type of cancer, other than certain common skin cancers, unless they have been cancer-free for at least 3 years
- People whose lymphoma is currently affecting the brain or spinal cord
- People with a history of lymphoma involving the heart, or a type of lymphoma linked to the Epstein-Barr virus
- People currently experiencing or about to experience a cancer-related emergency
- People who have recently received cancer treatment (systemic therapy or radiation) — specific timeframes apply (confirm with trial site)
- People still experiencing ongoing side effects from previous cancer treatment (excluding blood-related side effects)
- People who have previously received a donor stem cell transplant or an organ transplant from another person
- People who have had their own stem cells transplanted back into them within the past 6 weeks
- People who have previously received a gene-modified cell therapy — specific rules apply depending on which group (Cohort) is being considered, including restrictions related to certain CAR-T cell therapies (confirm with trial site)
- People with a primary immune system deficiency condition
- People with a history of an autoimmune disease that has caused damage to organs or has required recent treatment
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 000-000-0000
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
2 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Phase 1: Evaluate the safety and tolerability of a single dose of ronde-cel administered as a single agent; Phase 2: Estimate the efficacy of ronde-cel, as measured by overall response rate (ORR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.